MYHIBBIN

Growth

mycophenolate mofetil

NDAORALSUSPENSION
Approved
May 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

(MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective uncompetitive inhibitor of the two isoforms (type I and type II) of inosine monophosphate dehydrogenase (IMPDH) leading to inhibition of the de novo pathway of…

Clinical Trials (5)

NCT06615050Phase 3Recruiting

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

Started Apr 2025
572 enrolled
Graft-versus-host Disease (GVHD)
NCT05538208Phase 2Recruiting

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

Started Jun 2024
105 enrolled
Lupus Nephritis
NCT06114953Phase 4Unknown

Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients

Started Jan 2023
152 enrolled
Kidney Transplant Immunosuppression
NCT04039373Phase 1Completed

Effects of BMS-986256 at Steady State on the Single Dose Pharmacokinetics of Mycophenolate Mofetil

Started Jul 2019
15 enrolled
Healthy Participants
NCT03899103Phase 3Completed

Compare Efficacy and Safety of Repeated Courses of Rituximab to That of Maintenance Mycophenolate Mofetil Following Single Course of Rituximab Among Children With Steroid Dependent Nephrotic Syndrome

Started May 2019
100 enrolled
Steroid-Dependent Nephrotic Syndrome

Loss of Exclusivity

LOE Date
Aug 16, 2039
163 months away
Patent Expiry
Aug 16, 2039

Patent Records (5)

Patent #ExpiryTypeUse Code
11931455
Aug 16, 2039
Product
U-1752
12097284
Aug 16, 2039
Product
12097285
Aug 16, 2039
Product
U-1752
12194143
Aug 16, 2039
Product
U-1752
12226526
Aug 16, 2039
Product
U-1752